Journal article 570 views 79 downloads
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
,
Sarah Davies,
Umesh Dashora,
Smeeta Sinha,
Samuel Seidu,
Dipesh C. Patel,
Hannah Beba,
W. David Strain
Diabetes Therapy, Volume: 13, Issue: 5, Pages: 889 - 911
Swansea University Author:
Steve Bain
-
PDF | Version of Record
Copyright: The Author(s) 2022. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Download (654.49KB)
DOI (Published version): 10.1007/s13300-022-01242-y
Abstract
Disease burden in people with diabetes is mainly driven by long-term complications such as cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of the interconnection between the cardiovascular, renal and metabolic systems, through a continuous chain of events refe...
| Published in: | Diabetes Therapy |
|---|---|
| ISSN: | 1869-6953 1869-6961 |
| Published: |
Springer Science and Business Media LLC
2022
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa59763 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Disease burden in people with diabetes is mainly driven by long-term complications such as cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of the interconnection between the cardiovascular, renal and metabolic systems, through a continuous chain of events referred to as ‘the cardiorenal metabolic continuum’. Increasing evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes. Despite this robust evidence base, the complexity of label indications and misconceptions concerning potential side effects have resulted in a lack of clear understanding in primary care regarding the implementation of SGLT2is in clinical practice. With this in mind, we provide an overview of the clinical and economic benefits of SGLT2is across the cardiorenal metabolic continuum together with practical considerations in order to help address some of these concerns and clearly define the role of SGLT2is in primary care as a holistic outcomes-driven treatment with the potential to reduce disease burden across the cardiorenal metabolic spectrum. |
|---|---|
| Keywords: |
Cardiorenal metabolic continuum; Chronic kidney disease; Diabetes; Heart failure; SGLT2 inhibitors; Primary care |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This work was supported by a grant from AstraZeneca in respect of medical writing and publication costs. |
| Issue: |
5 |
| Start Page: |
889 |
| End Page: |
911 |